Art. -Nr.: HY-111674

Copy Link Print Information

LDC7559

23 Cited Publications

Kundenbewertung

Based on 23 publication(s) in Google Scholar

LDC7559 is a gasdermin D (GSDMD) inhibitor via blocking neutrophil extracellular trap (NET) in the late stages .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.51%
CAS. Nr.: 2407782-01-6
Formel: C₂₀H₁₉N₃O₃
Molecular Weight:349.38

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

LDC7559 Chemical Structure

CAS. Nr.: 2407782-01-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (23)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

LDC7559 is a gasdermin D (GSDMD) inhibitor via blocking neutrophil extracellular trap (NET) in the late stages ^[1].

IC₅₀ & Target

Gasdermin D^[1].

In Vitro

LDC7559 (1 and 5 μM) inhibits IL-1β release upon inflammasome activation, and significantly blocks the lethal effect of both human and murine GSDMD NT domains transfected into HEK293T cells^[3].
LDC7559 functions directly through blocking the activity of the GSDMD NT domain, rather than interfering with the activation and cleavage process^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2407782-01-6
Appearance Solid
Molecular Weight 349.38
Formel C₂₀H₁₉N₃O₃
Color White to light yellow
SMILES

COC1=C(C=CC=C1)C2=NN3C(COC(C=C(NC(C)=O)C=C4)=C4C3)=C2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (23)

All Cell Imaging/StainingBio/Physico-chemical AssayIPCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Autophagy

Lysosomal damage due to cholesterol accumulation triggers immunogenic cell death. [Abstract]

2025 May;21(5):934-956. PMID: 39663580

LDC7559 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 May;21(5):934-956. [Abstract]

LDC7559 (5 μM; 2+24 h)did not prevent cell death induced by indatraline and sertraline. U2OS cells were preincubated with a specific inhibitor for pyroptosis, LDC7559 (5 μM), for 2 h and then treated with indatraline (10 μM) or sertraline (10 μM) for 24 h.
Nat Cardiovasc Res

Stroke and myocardial infarction induce neutrophil extracellular trap release disrupting lymphoid organ structure and immunoglobulin secretion. [Abstract]

2024 May;3(5):525-540. PMID: 39195931
Stroke

Delayed DNase-I Administration but Not Gasdermin-D Inhibition Induces Hemorrhagic Transformation After Transient Focal Cerebral Ischemia in Mice. [Abstract]

2024 Nov;55(11):e297-e299. PMID: 39344516
Free Radic Biol Med

p67phox/NOX2 inhibits psoriasis by regulating the HIF-1α-glycolysis axis via p53-AMPK in keratinocytes. [Abstract]

2025 Sep:237:503-514. PMID: 40516795
J Agric Food Chem

Integrative Gut Microbiota and Metabolomic Analyses Reveal the PANoptosis- and Ferroptosis-Related Mechanisms of Chrysoeriol in Inhibiting Melanoma. [Abstract]

2024 Nov 13;72(45):25173-25185. PMID: 39497239
Life Sci

Phosphate burden induces vascular calcification through a NLRP3-caspase-1-mediated pyroptotic pathway. [Abstract]

2023 Nov 1:332:122123. PMID: 37742736

LDC7559 purchased from MedChemExpress. Usage Cited in: Life Sci. 2023 Nov 1:332:122123. [Abstract]

LDC7559 (2.5 μM; 8 days) and disulfiram, attenuated VSMC calcification. Alizarin red staining of A7r5 cells in HP or control medium for 8 days treated with LDC7559 (2.5 μM), disulfiram (5 nM), or IL-1RA (5 μM) (scale bar 100 μm). The results were semi-quantified by the concentrations of Alizarin red.

LDC7559 purchased from MedChemExpress. Usage Cited in: Life Sci. 2023 Nov 1:332:122123. [Abstract]

LDC7559 (2.5 μM; 8 days) treatment attenuated the cleavage of GSDMD and the release of LDHA in VSMCs subjected to a phosphate burden, indicating that pyroptosis was prevented. Immunoblots of A7r5 cell lysates and supernatants after 8 days of LDC7559 treatment.
Int Immunopharmacol

Neutrophil aconitate decarboxylase 1/itaconate axis suppresses extracellular traps via alkylating GSDMD and alleviates murine liver injury. [Abstract]

2026 Jun 1:178:116578. PMID: 41915992
Cancer Sci

BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia. [Abstract]

2025 Mar;116(3):673-689. PMID: 39652455

LDC7559 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2025 Mar;116(3):673-689. [Abstract]

LDC7559 (10 μM; L； 72 h) inhibited Mdivi‐1‐induced cell death in both BCR::ABL1‐positive and BCR::ABL1‐negative cells. Cell viabilities, live cell counts, and dead cell ratios were evaluated after 72 h of Mdivi‐1 treatment with or without inhibitors. Inhibitors used included: Caspase inhibitor Z‐VAD‐FMK (Z); gasdermin D inhibitor LDC7559 (L); necroptosis inhibitor Necrostatin‐1 (N); ferroptosis inhibitor Ferrostatin‐1.
FASEB J

Alum triggers infiltration of human neutrophils ex vivo and causes lysosomal destabilization and mitochondrial membrane potential-dependent NET-formation. [Abstract]

2020 Oct;34(10):14024-14041. PMID: 32860638
Eur J Immunol

PLC and PAD2 Regulate Extracellular Calcium-Triggered Release of Macrophage Extracellular DNA Traps. [Abstract]

2025 Apr;55(4):e202350942. PMID: 40170382

LDC7559 purchased from MedChemExpress. Usage Cited in: Eur J Immunol. 2025 Apr;55(4):e202350942. [Abstract]

LDC7559 (2 µM) and stimulated for 1 h with extracellular Ca2+ (1 mM). LDC7559 blocked inflammasome‐mediated pore formation.
Eur J Immunol

GSDMD-mediated NETosis promotes the development of acute respiratory distress syndrome. [Abstract]

2023 Jan;53(1):e2250011. PMID: 36250416
Naunyn Schmiedebergs Arch Pharmacol

Astragaloside IV-PESV facilitates pyroptosis by enhancing palmitoylation of GSDMD protein mediated by ZDHHC1. [Abstract]

2025 Apr 16. PMID: 40237800
Viruses

H6N6 Avian Influenza Virus Infection Induced Pyroptosis of M1 Macrophages by Activating Caspase-1. [Abstract]

2025 Nov 12;17(11):1492. PMID: 41305513
J Pharmacol Sci

Endothelial NLRP3-mediated pyroptosis induces blood-brain barrier and neuronal damage in Huntington's disease models. [Abstract]

2025 Dec;159(4):256-267. PMID: 41241436
J Med Microbiol

E. coli Nissle 1917 improves gut microbiota composition and serum metabolites to counteract atherosclerosis via the homocitrulline/Caspase 1/NLRP3/GSDMD axis. [Abstract]

2024 Dec 26:318:151642. PMID: 39742694
Mol Cell Toxicol

2025 Dec 8.
bioRxiv

2026 Mar 3.
Radiat Med Prot

2024 May 23.
Research Square Preprint

2024 Jan 19.
Cell Mol Biol (Noisy-le-grand)

GSDMD inhibitor protects chondrocyte from mechanical injury in human articular cartilage. [Abstract]

2023 Oct 31;69(10):227-232. PMID: 37953558
Research Square Preprint

2023 Aug 7.
Research Square Print

2023 Mar 14.
Elife

Pioneer neutrophils release chromatin within in vivo swarms. [Abstract]

2021 Jul 21:10:e68755. PMID: 34292151

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (286.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8622 mL

14.3111 mL

28.6221 mL

5 mM

0.5724 mL

2.8622 mL

5.7244 mL

10 mM

0.2862 mL

1.4311 mL

2.8622 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Spel L, et al. Gasdermin D opens the way for NETs. Nat Rev Rheumatol. 2018 Dec;14(12):690-692. [Content Brief]

[2]. Sollberger G, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol. 2018 Aug 24;3(26). pii: eaar6689. [Content Brief]

[3]. Ankit Pandeya, et al. Gasdermin D (GSDMD) as a New Target for the Treatment of Infection. Medchemcomm. 2019 Apr 4;10(5):660-667. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8622 mL	14.3111 mL	28.6221 mL	71.5553 mL
	5 mM	0.5724 mL	2.8622 mL	5.7244 mL	14.3111 mL
	10 mM	0.2862 mL	1.4311 mL	2.8622 mL	7.1555 mL
	15 mM	0.1908 mL	0.9541 mL	1.9081 mL	4.7704 mL
	20 mM	0.1431 mL	0.7156 mL	1.4311 mL	3.5778 mL
	25 mM	0.1145 mL	0.5724 mL	1.1449 mL	2.8622 mL
	30 mM	0.0954 mL	0.4770 mL	0.9541 mL	2.3852 mL
	40 mM	0.0716 mL	0.3578 mL	0.7156 mL	1.7889 mL
	50 mM	0.0572 mL	0.2862 mL	0.5724 mL	1.4311 mL
	60 mM	0.0477 mL	0.2385 mL	0.4770 mL	1.1926 mL
	80 mM	0.0358 mL	0.1789 mL	0.3578 mL	0.8944 mL
	100 mM	0.0286 mL	0.1431 mL	0.2862 mL	0.7156 mL

Keywords

LDC7559

23 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

LDC7559

Immunology/Inflammation Compound Library

Pyroptosis Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) LDC7559

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LDC7559

Immunology/Inflammation Compound Library

Pyroptosis Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) LDC7559

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LDC7559 Related Classifications

HY-111674 Related Classifications